In the spring of 2023, Cytokinetics announced a pivot. Following the failure of ALS drug candidate reldesemtiv in a late-stage trial, the California-based biotech said it would focus its resources on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback